Insider Selling: GeneDx Holdings Corp. (NASDAQ:WGS) CFO Sells $20,616.57 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 263 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $78.39, for a total transaction of $20,616.57. Following the sale, the chief financial officer now directly owns 23,406 shares in the company, valued at approximately $1,834,796.34. This trade represents a 1.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Kevin Feeley also recently made the following trade(s):

• On Thursday, November 21st, Kevin Feeley sold 12,019 shares of GeneDx stock. The stock was sold at an average price of $73.76, for a total value of $886,521.44.
• On Tuesday, October 29th, Kevin Feeley sold 274 shares of GeneDx stock. The stock was sold at an average price of $66.60, for a total transaction of $18,248.40.
• On Monday, September 9th, Kevin Feeley sold 895 shares of GeneDx stock. The stock was sold at an average price of $33.33, for a total transaction of $29,830.35.

GeneDx Trading Down 1.0 %

GeneDx stock opened at $78.85 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40. The business’s 50-day simple moving average is $66.00 and its 200-day simple moving average is $42.89. The firm has a market capitalization of $2.17 billion, a PE ratio of -25.60 and a beta of 2.03. GeneDx Holdings Corp. has a 52 week low of $1.45 and a 52 week high of $89.11.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.25. The firm had revenue of $76.90 million for the quarter, compared to analyst estimates of $64.98 million. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The company’s quarterly revenue was up 44.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.82) earnings per share. Equities research analysts forecast that GeneDx Holdings Corp. will post -0.24 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Wells Fargo & Company lifted their price target on GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday, October 30th. The Goldman Sachs Group raised their target price on GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Finally, Craig Hallum upped their price target on GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $59.33.

Hedge Funds Weigh In On GeneDx

A number of hedge funds have recently made changes to their positions in the business. Acadian Asset Management LLC bought a new stake in shares of GeneDx during the second quarter worth $34,000. nVerses Capital LLC acquired a new stake in shares of GeneDx during the second quarter worth $50,000. CWM LLC acquired a new position in shares of GeneDx during the 3rd quarter worth about $89,000. SG Americas Securities LLC acquired a new position in GeneDx during the third quarter valued at approximately $198,000. Finally, Point72 DIFC Ltd acquired a new position in shares of GeneDx in the 3rd quarter valued at $220,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.